This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tripathy, D. Search for Related Content PubMed PubMed Citation Articles by Tripathy, D.

Breast Cancer

Capecitabine in Combination with Novel Targeted Agents in the Management of Metastatic Breast Cancer: Underlying Rationale and Results of Clinical Trials

Komen/University of Texas Southwestern Breast Cancer Research Program, University of Texas Southwestern Medical Center, Dallas, Texas, USA

Key Words. Capecitabine • Breast neoplasm • Biological response modifiers • Antineoplastic agents

Correspondence: Debu Tripathy, M.D., Physicians' Education Resource, 3500 Maple Avenue, Suite 700, Dallas, Texas 75219, USA. Telephone: 214-367-3500; e-mail: debu.tripathy{at}pergrouplp.com

At present there is no established standard of care for metastatic breast cancer and prognosis remains poor, although the use of newer chemotherapeutic regimens has led to modest improvements in survival. Capecitabine, an oral prodrug of 5-fluorouracil, is a promising addition to these approaches, having already shown single-agent activity against metastatic breast cancer. Following a pivotal trial demonstrating that capecitabine confers increased survival when used in combination with docetaxel, it is being investigated intensively in combined regimens using other standard chemotherapeutic agents, as well as with novel molecularly targeted therapies.

Among the novel agents, the most intensively studied in combination with capecitabine is trastuzumab. Despite preclinical data suggesting that these two agents might not show additive effects, clinical trials have been very encouraging for both heavily pretreated patients and for patients receiving first-line therapy in the metastatic setting. This work is being further extended in an ongoing trial in the neoadjuvant setting. An initial trial in combination with bevacizumab, enrolling heavily pretreated patients, was less successful, but following the example of the E2100 trial, this combination is being re-examined in less heavily treated patients. In addition, this review discusses ongoing trials with an array of newer molecularly targeted agents. Significant improvement in time to progression has already been demonstrated in the combination of lapatinib and capecitabine compared with capecitabine monotherapy; for the most part, however, these trials are still in early stages.

Disclosure of potential conflicts of interest is found at the end of this article.

This article has been cited by other articles:

				V. Sarli and A. Giannis Targeting the Kinesin Spindle Protein: Basic Principles and Clinical Implications Clin. Cancer Res., December 1, 2008; 14(23): 7583 - 7587. [Abstract] [Full Text] [PDF]